- Home
- CRIS vs APM Comparison
CRIS vs APM Comparison
Compare CRIS & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- APM
- Stock Information
- Founded
- CRIS 2000
- APM 2010
- Country
- CRIS United States
- APM United Kingdom
- Employees
- CRIS N/A
- APM N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- CRIS Health Care
- APM Health Care
- Exchange
- CRIS Nasdaq
- APM Nasdaq
- Market Cap
- CRIS 22.9M
- APM 18.9M
- IPO Year
- CRIS 2000
- APM 2018
- Fundamental
- Price
- CRIS $1.65
- APM $2.09
- Analyst Decision
- CRIS Strong Buy
- APM
- Analyst Count
- CRIS 2
- APM 0
- Target Price
- CRIS $16.50
- APM N/A
- AVG Volume (30 Days)
- CRIS 66.6K
- APM 437.5K
- Earning Date
- CRIS 11-13-2025
- APM 04-30-2025
- Dividend Yield
- CRIS N/A
- APM N/A
- EPS Growth
- CRIS N/A
- APM N/A
- EPS
- CRIS N/A
- APM N/A
- Revenue
- CRIS $11,405,000.00
- APM N/A
- Revenue This Year
- CRIS $2.72
- APM N/A
- Revenue Next Year
- CRIS $8.27
- APM N/A
- P/E Ratio
- CRIS N/A
- APM N/A
- Revenue Growth
- CRIS 12.24
- APM N/A
- 52 Week Low
- CRIS $1.02
- APM $0.46
- 52 Week High
- CRIS $5.51
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- CRIS 42.93
- APM 54.81
- Support Level
- CRIS $1.58
- APM $1.74
- Resistance Level
- CRIS $1.74
- APM $2.45
- Average True Range (ATR)
- CRIS 0.09
- APM 0.19
- MACD
- CRIS -0.00
- APM 0.04
- Stochastic Oscillator
- CRIS 17.34
- APM 50.63
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.